Success Metrics

Clinical Success Rate

93.3%

Based on 14 completed trials

Completion Rate

93%(14/15)

Active Trials

6(21%)

Results Posted

43%(6 trials)

Terminated

1(3%)

Phase Distribution

Ph phase_4

Ph phase_2

41%

Ph phase_3

Ph not_applicable

34%

Ph phase_1

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution29 total trials

Phase 1Safety & dosage

4(13.8%)

Phase 2Efficacy & side effects

12(41.4%)

Phase 3Large-scale testing

2(6.9%)

Phase 4Post-market surveillance

1(3.4%)

N/ANon-phased studies

10(34.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(8)

Completed(14)

Terminated(2)

Other(5)

Detailed Status

Completed14

unknown5

Recruiting4

Active, not recruiting2

Enrolling by invitation1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

93.3%

Most Advanced

Phase 4

Trials by Phase

Phase 14 (13.8%)

Phase 212 (41.4%)

Phase 32 (6.9%)

Phase 41 (3.4%)

N/A10 (34.5%)

Trials by Status

enrolling_by_invitation13%

terminated13%

completed1448%

recruiting414%

unknown517%

not_yet_recruiting13%

withdrawn13%

active_not_recruiting27%

Recent Activity

6 active trials

Showing 5 of 29

recruitingnot_applicable

Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation

NCT07297576

enrolling_by_invitationnot_applicable

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more

NCT07297576Not Applicable

Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation

Recruiting

NCT04805957Not Applicable

Validation Digital Bio-markers During Sulforaphane Treatment.

Enrolling By Invitation

NCT02677051Phase 2

Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism

Active Not Recruiting

NCT07047976Not Applicable

Mechanism Study of Sulforaphane in ASD Improvement

Withdrawn

NCT04848792Not Applicable

Treatment Strategy to Enhance Nrf2 Signaling in Older Adults

Completed

NCT03232138Phase 2

Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers

Completed

NCT03934905Phase 1

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Recruiting

NCT05408559Phase 1

Prevention of Age-associated Cardiac and Vascular Dysfunction Using Avmacol ES

Recruiting

NCT06594536Not Applicable

Study of the Efficacy of Sulforaphane in Children Aged 6 to 12 With Attention Deficit Disorder With or Without Hyperactivity

Not Yet Recruiting

NCT05653492Phase 2

Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease

Active Not Recruiting

NCT05153174Phase 1

Study of Sulphoraphane in Chronic Kidney Disease

Completed

NCT03932136Phase 3

Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

Recruiting

NCT05233579Not Applicable

Open-Label Trial of Sulforaphane in Premutation Carriers With FXTAS

Completed

NCT05084365Phase 2

A 6-month Study to Evaluate Sulforaphane Effects in PD Patients

Unknown

NCT03126539Phase 2

Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure

Terminated

NCT04521868Phase 2

A 6-month Study to Evaluate Sulforaphane Effects in Schizophrenia Patients

Completed

NCT03878368Not Applicable

Broccoli In Osteoarthritis

Completed

NCT05224492Phase 4

Sulforaphane Use to Effect Inflammatory and Metabolic Changes in Virally Suppressed HIV Patients

Unknown

NCT02801448Phase 2

Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes

Completed

NCT02561481Phase 1

Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)

Completed

Drug Details

Intervention Type: DIETARY SUPPLEMENT
Total Trials: 29